Predictive Oncology (POAI) stock price, revenue, and financials

Predictive Oncology annual revenue was $1.41 m in FY 2018

$286.2 K

Predictive Oncology Revenue Q2, 2019
Predictive Oncology Gross profit (Q2, 2019)167.8 K
Predictive Oncology Gross profit margin (Q2, 2019), %58.6%
Predictive Oncology Net income (Q2, 2019)1.5 M
Predictive Oncology Cash, 30-Jun-201969.6 K

Predictive Oncology Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

468.1k951.6k654.4k456.5k654.8k1.4m

Revenue growth, %

103%(31%)

Cost of goods sold

189.7k385.3k304.0k181.6k148.0k415.8k

Gross profit

278.4k566.2k350.4k274.9k506.8k995.9k

Gross profit Margin, %

59%60%54%60%77%71%

General and administrative expense

7.5m3.4m5.2m6.0m4.6m

Operating expense total

7.5m3.4m5.2m6.0m4.6m

Interest expense

636.5k377.7k390.9k3.0

Net Income

(9.4m)(6.8m)(4.8m)(6.5m)

Predictive Oncology Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

102.0k16.4k4.9m1.8m766.2k162.2k

Accounts Receivable

57.5k38.3k38.9k137.5k232.6k

Inventories

122.2k367.4k231.7k272.2k265.0k241.1k

Current Assets

382.0k631.3k5.4m2.6m2.4m1.5m

PP&E

158.1k139.6k87.7k180.5k

Total Assets

593.4k901.0k5.6m2.8m3.6m3.7m

Accounts Payable

1.1m2.2m650.4k220.1k140.5k445.7k

Current Liabilities

3.5m6.2m1.5m1.6m932.3k3.7m

Total Liabilities

3.8m1.5m1.9m932.3k3.7m

Preferred Stock

792.0

Additional Paid-in Capital

23.3m30.1m44.5m(47.9m)(57.4m)(63.0m)

Retained Earnings

(40.5m)47.0m54.8m63.1m

Total Equity

(3.2m)(5.5m)4.1m923.7k2.7m53.5k

Financial Leverage

-0.2 x-0.2 x1.4 x3 x1.3 x69.4 x

Predictive Oncology Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(9.4m)(6.8m)(4.8m)(6.5m)(7.7m)(10.1m)

Depreciation and Amortization

148.8k63.0k78.6k82.4k71.6k147.6k

Accounts Receivable

(57.5k)39.7k19.3k(636.0)(98.6k)(95.1k)

Inventories

23.0k(245.2k)135.6k(40.5k)7.2k24.0k

Accounts Payable

429.0k1.1m(1.5m)(430.3k)(79.6k)305.2k

Cash From Operating Activities

(3.9m)(3.4m)(7.5m)(4.4m)(5.3m)

Purchases of PP&E

(162.8k)(101.4k)(32.5k)(32.8k)(45.1k)(177.7k)

Cash From Investing Activities

(216.1k)(121.2k)(60.6k)(422.9k)(1.7m)(1.1m)

Cash From Financing Activities

4.2m3.4m12.4m1.7m5.1m5.8m

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(1.8m)(4.1m)(6.6m)(3.3m)(1.8m)

Depreciation and Amortization

18.2k41.1k105.6k39.5k259.4k

Accounts Receivable

149.6k238.6k90.0k15.9k14.2k52.8k23.6k45.0k68.5k(104.3k)(177.8k)(101.1k)59.2k141.3k

Inventories

360.7k315.6k301.4k257.7k236.9k256.5k292.2k289.2k249.2k(7.5k)20.4k(13.1k)(48.0k)(55.7k)

Accounts Payable

1.6m1.6m2.5m2.5m1.1m791.7k750.5k648.1k79.3k45.8k25.1k268.6k(13.5k)718.5k

Cash From Operating Activities

(4.1m)(2.0m)(4.0m)

Purchases of PP&E

(32.8k)(130.0k)(170.0k)

Cash From Financing Activities

3.0m3.3m3.6m3.6m4.5m

Predictive Oncology Ratios

USDY, 2019

Financial Leverage

1.4 x